Paragon Sports Medicine

Home/ Peptides/ KPV

Back to all peptides

KPV

KPV is a three-amino-acid fragment of a hormone your body already makes. Small, targeted, anti-inflammatory. It has been studied extensively in the lab for inflammatory bowel disease, skin conditions, wound healing, and joint irritation.
‍
Compliance Notice: Important status notice. KPV is not FDA approved for any therapeutic use. The FDA formerly classified it as Category 2 (substance with safety concerns), citing a lack of human exposure data by any administration route. That designation was withdrawn on 22 April 2026; its compounding status is pending FDA review. KPV is not currently listed on the WADA Prohibited List, but WADA updates its list annually and athletes should verify status before any use.

Chemical structure diagram of KPV tripeptide molecule with labeled atoms and bonds.
Smiling older man jogging outdoors in a dark long-sleeve zip-up shirt during golden hour.Smiling older man jogging outdoors in a dark athletic zip-up shirt during golden hour.

Overview

KPV stands for the three amino acids that make it up: lysine, proline, valine. It is the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring signaling molecule in your body. The rest of that hormone does a lot of things (pigmentation, appetite, sexual response). KPV does not do any of that. It kept the anti-inflammatory activity and left the rest behind.

That selectivity is the point. In laboratory studies, KPV dials down the two inflammatory pathways that drive most chronic inflammation (NF-kB and MAPK) without shutting down your immune system the way broad immunosuppressants can. It is also unusually small for a peptide, which means a portion of it survives the gut and is carried directly into inflamed tissue by a transporter called PepT1. That transporter is upregulated in inflamed tissue, so KPV concentrates where inflammation is active. A self-targeting feature, in effect.

The preclinical data is promising. What it is not is equally clear. There are no completed human clinical trials. The mechanism is well characterized in cells and animals. Human outcomes still need to be established by proper randomized trials.

Person's hand wrapped in white bandage being held by the other hand near a warm fire in the background.

CHEMICAL STRUCTURE & PROPERTIES

  • Molecular Formula: C16H30N4O4
  • Molecular Weight: 342.43 Da
  • Sequence: Lys-Pro-Val (tripeptide)
  • Origin: C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH)
  • CAS Number: 69663-38-3
  • Half-life: Short; route-dependent
  • Stability: Lyophilised powder; store at 2 degrees C to 8 degrees C before reconstitution
  • Route: Subcutaneous injection, oral, or topical depending on indication

Mechanism of Action

KPV exerts its anti-inflammatory effects through multiple interconnected molecular pathways:

NF-kB and MAPK Pathway Suppression

KPV's primary anti-inflammatory mechanism operates at two of the most important signaling nodes in chronic inflammation:
  • KPV suppresses NF-kB signaling, one of the two major pathways driving chronic inflammation
  • KPV suppresses MAPK signaling, the second major driver of chronic inflammatory activity
  • This dual suppression reduces production of pro-inflammatory cytokines without broadly shutting down immune function
  • The selectivity distinguishes KPV from broad immunosuppressants, which carry wider systemic risk

PepT1-Mediated Gut Targeting

KPV's small size gives it an unusual property among peptides -- partial oral bioavailability with active tissue targeting:
  • KPV is small enough that a portion of an oral dose survives the digestive tract intact
  • It is actively transported into inflamed intestinal cells by the PepT1 transporter
  • PepT1 is upregulated in inflamed tissue, so KPV concentrates where gut inflammation is most active
  • This self-targeting mechanism is the basis for its study in inflammatory bowel disease

Skin and Wound Healing Effects

KPV's anti-inflammatory activity extends to dermal tissue and wound repair:
  • KPV reduces inflammatory signaling in skin cells exposed to inflammatory stimuli
  • A 2025 study confirmed KPV's effects on inflammatory signaling in human skin cells exposed to air pollution
  • Topical KPV preparations have been studied for psoriasis and atopic dermatitis applications
  • In wound models, KPV supports the transition out of the inflammatory phase to allow tissue repair

Joint and Systemic Anti-Inflammatory Effects

For patients with joint irritation and systemic inflammatory load, KPV's pathway effects extend beyond the gut:
  • Subcutaneous KPV reaches systemic circulation and exerts anti-inflammatory effects at the signaling level
  • Joint inflammation driven by NF-kB and MAPK pathways is a candidate target based on mechanism
  • Athletes with gut irritation tied to training load are a specific application given the combined gut and systemic burden

Areas Investigated in

the Research Literature

Inflammatory Bowel Disease

Primary Investigation: The landmark 2008 Dalmasso study established that KPV is actively transported into inflamed gut cells by PepT1, suppresses NF-kB and MAPK signaling, and reduced colitis severity in two mouse models of IBD.

  • Oral KPV reduced colitis severity in two distinct mouse models of inflammatory bowel disease
  • A 2016 follow-up study showed KPV reduced colitis-associated tumor formation
  • The anti-tumor effect disappeared in mice without functional PepT1, confirming the transport mechanism is required
  • A 2017 nanoparticle delivery study achieved effective anti-inflammatory activity at a dose thousands of times lower than free KPV

Mechanism: KPV is transported by PepT1 into inflamed intestinal tissue, where it suppresses NF-kB and MAPK signaling and reduces pro-inflammatory cytokine production -- concentrating activity where gut inflammation is most active.

Skin Inflammation and Wound Healing

Emerging Applications: Research has expanded into dermatological and wound healing applications, with a 2025 study confirming KPV's effects in human skin cells.

  • Topical KPV preparations have been studied for psoriasis and atopic dermatitis
  • A 2025 study confirmed KPV's effects on inflammatory signaling in human skin cells exposed to air pollution
  • In wound models, KPV supports the resolution of the inflammatory phase and the transition to tissue repair
  • Advanced delivery systems including nanoparticle formulations have been developed to improve skin penetration

Mechanism: KPV reduces NF-kB and MAPK-driven inflammatory signaling in dermal tissue, supporting resolution of chronic skin inflammation and creating conditions for wound healing to proceed.

Joint Irritation and Recovery

Research Potential: KPV's systemic anti-inflammatory profile makes it a candidate for joint and recovery applications, particularly in patients with elevated inflammatory load from training or chronic joint irritation.

  • Subcutaneous KPV reaches systemic circulation and targets the same inflammatory pathways active in joint tissue
  • Athletes with gut irritation tied to training load present a combined gut and systemic application
  • Joint inflammation driven by NF-kB and MAPK activity is a mechanistic candidate

Mechanism: KPV's suppression of NF-kB and MAPK signaling extends systemically via subcutaneous administration, reducing the inflammatory burden in joint tissue and supporting recovery from training-driven inflammation.

Woman in workout clothes outdoors clutching her abdomen in pain with eyes closed.

Current Clinical Evidence

Published Preclinical Studies

Two decades of preclinical research have built a consistent picture. In cell culture and animal models, KPV reduces inflammatory signaling that drives chronic disease, does it at very low concentrations, and does it without the side effects of broader anti-inflammatories.

  • The 2008 Dalmasso study established the PepT1 transport mechanism and demonstrated colitis reduction in two mouse models
  • The 2016 follow-up study showed reduced colitis-associated tumor formation dependent on PepT1 function
  • A 2017 nanoparticle study achieved effective anti-inflammatory activity at a dose thousands of times lower than free KPV
  • A 2025 study confirmed KPV effects on inflammatory signaling in human skin cells

What the Research Has Not Yet Settled

The preclinical signal is consistent. The human clinical trial data does not yet exist.

  • There are no completed human clinical trials for KPV
  • The FDA has stated explicitly that it lacks human exposure data for KPV by any administration route
  • Drug interaction data with biologics, corticosteroids, and other immunomodulators has not been formally studied
  • Long-term repeated-dose safety in humans has not been characterized

Research Limitations

Current evidence is constrained by:

  • Absence of any completed human clinical trials
  • Former FDA Category 2 classification, reflecting stated safety concerns and lack of human exposure data; withdrawn 22 April 2026
  • All efficacy data derived from cell culture and animal models
  • No formal pharmacokinetic characterization in humans across oral, subcutaneous, or topical routes
  • Drug interaction studies have not been conducted

Safety Considerations

Preclinical Safety Data

In preclinical studies, KPV has been well tolerated across routes and models.

  • KPV derives from a hormone your body already makes (alpha-MSH)
  • It is below the minimum size for immune system recognition as a foreign peptide
  • No tumor-promoting or hepatotoxic signal has appeared in published animal data
  • Reported side effects in clinical use have been mild when they occur: occasional injection site reactions, rare gastrointestinal discomfort at higher oral doses

Theoretical Concerns

Potential considerations include:

  • No completed human clinical trials - the FDA has stated it lacks human exposure data by any route
  • Drug interaction data with biologics, corticosteroids, and calcineurin inhibitors has not been formally studied
  • Combining immune-modulating tools is a clinical decision, not a catalog choice
  • Long-term repeated-dose safety has not been characterized

Contraindications

Populations excluded from published studies, and where use would be contraindicated:

  • Patients with an active bacterial, viral, or fungal infection
  • Pregnancy, planned pregnancy, or breastfeeding
  • Patients on biologics or other strong immunomodulators that have not been formally evaluated for KPV interaction
  • Anyone whose case has not been reviewed by a qualified clinician familiar with their full history

Regulatory Status and Legal Considerations

Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.

FDA Status

No Approved Medical Use:
  • KPV is not FDA approved for any therapeutic indication
  • The FDA previously classified KPV as Category 2. As of April 22, 2026, KPV is listed as Nominated but Withdrawn from Category 2.
  • The FDA previously noted it lacked human exposure data for KPV by any administration route - this was part of the basis for the original Category 2 nomination.
  • The KPV Category 2 nomination was withdrawn on April 22, 2026. On 23-24 July 2026 the FDA Pharmacy Compounding Advisory Committee recommended KPV for inclusion on the 503A bulk drug substances list. The recommendation is advisory and non-binding; final FDA rulemaking is pending and compounding is not authorized in the interim. Consult current FDA guidance before compounding.

WADA Status

Current Classification:
  • KPV is not currently listed on the WADA Prohibited List
  • WADA reviews its prohibited list annually and category definitions can evolve
  • If you compete in a WADA-regulated sport, verify current status at wada-ama.org before any consideration
  • Talk to your sport governing body before considering any compound in this category

Legal Availability

Legal and Regulatory Status:
  • Research use of KPV is legal in the United States
  • It is not approved as a therapeutic, which is a different question from legality
  • Products sold outside licensed channels carry sterility and purity risks that no authority audits
Young woman in brown activewear sitting cross-legged on a green yoga mat stretching arms upward with eyes closed in a sunlit room.

Conclusion

What the evidence supports.

KPV is the C-terminal tripeptide of alpha-MSH, and the preclinical case for it is coherent: it appears to act on inflammatory signaling without the pigmentation effects of the parent molecule. Animal and cell-culture work has reported reduced inflammatory cytokine expression across several models.

That work has not been carried into human trials. There are no controlled clinical studies of KPV in any inflammatory condition, no established dosing, and no long-term safety data. KPV is not FDA approved. This page summarizes the preclinical research and nothing further.

KPV SCIENTIFIC

DATA SUMMARY

Parameter
Value
Peptide Structure
Tripeptide: Lysine-Proline-Valine (K-P-V), α-peptide bonds
Molecular Weight
342.43 Da
Isoelectric Point
8.14 (positively charged at physiological pH)
Origin
C-terminal tripeptide (residues 11–13) of α-melanocyte stimulating hormone (α-MSH; full sequence SYSMEHFRWGKPV). KPV exerts stronger anti-inflammatory activity than the full α-MSH parent peptide in several models.
Chemical Stability
More stable than parent α-MSH due to smaller size and simplified structure
Bioavailability
Oral bioavailability via PepT1 transporter (di/tripeptide transporter); IV and subcutaneous administration also effective
Transport Mechanism
Actively transported into intestinal epithelial and immune cells via hPepT1 (SLC15A1). PepT1 is normally expressed in the small intestine and specifically upregulated in the colon during IBD, enabling selective targeting of inflamed tissue. KPV has a high affinity for hPepT1 (Km ~160 µM in Caco2-BBE cells — among the lowest Kms reported for this transporter). Effect abolished in PepT1-negative cells.
Pathway
Effect
NF-κB Inhibition
Primary intracellular mechanism: blocks NF-κB activation by inhibiting IκB-α phosphorylation and degradation, preventing nuclear translocation of NF-κB and transcription of pro-inflammatory genes
MAPK Pathway Suppression
Inhibits ERK1/2, JNK, and p38 MAPK phosphorylation and activation
Cytokine Modulation
Reduces IL-1β, IL-6, TNF-α, and IFN-γ secretion; blocks IL-1β-mediated inflammatory responses; IL-8 reduction also demonstrated in epithelial cell models
Melanocortin Receptor Independence
KPV does not bind MC1R, MC3R, or MC5R and does not increase intracellular cAMP in intestinal epithelial and immune cells, confirming non-MCR mechanism in those tissues. Anti-inflammatory activity retained in MC1R-deficient mice. Note: in bronchial airway epithelial cells, MC3R involvement has been reported (Land SC, PLoS ONE 2012), indicating cell-type-specific receptor interactions cannot be fully excluded.
PepT1-Mediated Cellular Uptake
Anti-inflammatory effect depends on cellular internalization via PepT1 transporter; effect abolished in PepT1-negative cells and in PepT1-knockout mice in vivo
Intracellular Action
Acts inside cells to directly inactivate inflammatory pathways, rather than via surface receptor signaling. Distinguishes KPV from most anti-inflammatory drugs that act at membrane receptors.
IL-1β Pathway Interaction
Blocks surface binding of radiolabelled IL-1β to T cells and inhibits the hyperalgesic effect of IL-1β in vivo — a mechanism complementary to PepT1/NF-κB inhibition (Brzoska et al. 2008; Getting et al. 2002)
Application
Model
Dose / Route
Reported outcome (model)
Inflammatory Bowel Disease
DSS and TNBS-induced colitis (mice)
100 µM oral (drinking water) (animal/preclinical)
Reduced weight loss, decreased colonic MPO activity, reduced pro-inflammatory cytokine mRNA, improved colon histology
Colitis-Associated Cancer
Mouse CAC model (hPepT1 transgenic and knockout mice)
Oral administration
Significant reduction in tumor number and size; effect abolished in PepT1-knockout mice, confirming PepT1-dependence. hPepT1 overexpression worsened CAC; KPV partially reversed this effect.
Contact Hypersensitivity
Murine contact dermatitis
Topical and systemic
Suppressed contact hypersensitivity; reduced inflammatory cytokines in keratinocytes; effect retained in MC1R-deficient mice
Transdermal Delivery
Human skin (ex vivo, dermatomed)
Iontophoresis (ITP) + microneedles (MN)
Passive diffusion below limit of detection (0.01 µg/mL). MN alone: 4.4 µg/cm²/h. ITP+MN combination: 35-fold enhancement vs. MN alone.
Particulate Matter Protection
PM10-exposed HaCaT keratinocytes
50 µg/mL (animal/preclinical)
Restored cell viability, reduced ROS production, inhibited caspase-3 activation and IL-1β secretion
Antimicrobial Activity
In vitro pathogen studies (Cutuli et al. 2000)
Picomolar to micromolar concentrations (animal/preclinical; broad range; concentration-dependent)
Inhibitory effects against S. aureus and C. albicans demonstrated at physiological concentrations. Dimeric form ([Ac-CKPV]₂) showed enhanced candidacidal activity. Note: these data are preliminary — independent replication studies produced mixed results, and the antimicrobial evidence base should be interpreted cautiously.
Study Type
Population
Results
Limitations
K[D]PT Phase 2 UC Trial (related peptide)
UC patients
8-week double-blind trial of K[D]PT (Lys-D-Pro-Thr) — a structurally related but chemically distinct tripeptide derived from IL-1β(193–195), not from KPV. Oral dosing at 20, 50, or 100 mg twice daily; assessed by Colitis Activity Index (CAI). No completed human clinical trials for KPV itself have been published.
This trial evaluated K[D]PT, not KPV — the two peptides differ in sequence and origin. No peer-reviewed human efficacy data exists for KPV specifically.
Transdermal Permeation Study
Human skin (dermatomed, ex vivo)
Enhanced delivery via iontophoresis + microneedle combination demonstrated feasibility for dermatological applications
Ex vivo only; no in vivo human data
Nanoparticle Formulation
Preclinical with clinical potential
HA-functionalized PLGA nanoparticles (~272 nm, −5.3 mV) showed superior colonic targeting and anti-inflammatory effects vs. free KPV in murine colitis models
No human studies; formulation development stage only
General Human Tolerability
Limited clinical use
No formal human safety or tolerability trials have been conducted. Any tolerability observations are anecdotal from uncontrolled clinical use, not from published studies.
No large-scale safety studies; comprehensive clinical trials required before any efficacy or safety conclusion can be drawn in humans
Overall Evidence Level
N/A
Entire efficacy evidence base for KPV is preclinical (cell culture and animal models). The mechanistic foundation — PepT1-mediated uptake, NF-κB inhibition, MAPK suppression — is well-established in vitro and in rodent models. Human translation has not been demonstrated.
No completed human clinical trials for KPV; no published pharmacokinetic data in humans; regulatory approval pathway not established
Parameter
Finding
Acute Tolerability
Well tolerated in preclinical (animal and cell) studies; no formal human safety studies have been conducted; any human tolerability data is anecdotal from uncontrolled clinical use only
Potential Side Effects
Mild: transient skin irritation (topical), possible GI upset at higher oral doses, occasional fatigue or headache — all anecdotal from clinical use, not from controlled trials
Immune Function
Regulates inflammation without broad immune suppression; lower theoretical risk profile than corticosteroids
Pigmentation
Unlike α-MSH, KPV does not cause skin darkening or melanotropic effects — confirmed across multiple studies
Long-term Safety
No long-term safety data available; chronic daily use effects entirely unknown
Special Populations
Pediatric, elderly, and immunocompromised populations not systematically studied in any published work
Drug Interactions
No known significant drug interactions; simple tripeptide structure theoretically reduces interaction risk; no formal interaction studies have been conducted
Route
Application
Notes
Oral (Capsules/Tablets)
Inflammatory bowel disease, systemic inflammation
Active transport via PepT1 in small intestine; enhanced uptake in inflamed colon where colonic PepT1 is upregulated by IBD
Topical (Creams/Gels)
Skin conditions: eczema, psoriasis, dermatitis, wound healing
Direct application to affected areas; passive diffusion through intact skin is below detection limits — enhancement technologies (iontophoresis) required for meaningful penetration
Injectable (SC/IV)
Systemic effects, specific therapeutic applications
Requires reconstitution from lyophilized powder with sterile or bacteriostatic water
Nasal Sprays
Under investigation for neurological applications
Research stage; potential CNS access is hypothetical — no published intranasal KPV + CNS efficacy data
Nanoparticle Formulations
Enhanced colonic delivery for IBD
HA-functionalized PLGA nanoparticles (~272 nm) demonstrate superior colonic targeting and efficacy vs. free KPV in preclinical models (Xiao et al. Mol Ther 2017)
Modified Analogues
Improved stability and bioavailability
Glycoalkylated KPV shows complete resistance to pronase degradation; dimeric form ([Ac-CKPV]₂) shows enhanced antimicrobial activity
Authority
Classification
Status
FDA (USA)
Formerly Category 2 (503A list); designation withdrawn 22 April 2026
Not approved for any therapeutic indication. Nominated to Category 2 in late 2023–2024; that nomination was withdrawn on 22 April 2026. Withdrawal does not authorize compounding — KPV is not on the 503A bulks list.
WADA
Not explicitly prohibited
KPV not specifically named on the WADA Prohibited List; unlikely to fall under S2 categories as it lacks performance-enhancing properties
Research Use
Investigational compound
Available as unregulated research-grade peptide from research chemical suppliers (not pharmaceutical grade); compounding access currently restricted in the US pending formal FDA reclassification
Pharmaceutical Development
Preclinical / No completed human trials
Multiple institutions conducting development programs; IBD and dermatology are primary focus areas. No human efficacy trials for KPV have been completed and published.
Patent Status
Various patents exist
U.S. patents filed for dermatological applications; formulation patents for enhanced delivery systems

About this library

This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.

This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.

Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. KPV is not FDA approved for any therapeutic indication and was formerly classified as Category 2 on the basis of identified safety concerns and a lack of human exposure data by any administration route; that designation was withdrawn on 22 April 2026. Compounding pharmacies in the United States cannot prepare it. Patients should consult with a qualified clinician and ensure regulatory compliance before considering any use of KPV.

Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.

References

01
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008.
02
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.
03
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017.
04
Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016.
05
In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomater Sci. 2021.
06
Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010.